EGFR and non-small cell lung carcinoma: As an example, the OPTIMAL [8, 9] and the Lux-Lung 3 [10] trials compared the efficacy and tolerability of two tyrosine kinase inhibitor (erlotinib and afatinib, respectively) versus chemotherapy in first-line line treatment of patients with advanced EGFR mutation-positive NSCLC.